糖尿病患者体内制造胰岛素的胰岛贝塔细胞通常缺失或功能失调，哈佛医学院的科研团队透过基因筛选技术，成功找到能促使胰管细胞转化为类似贝塔细胞的关键基因 ALDH3B2。当该基因被静音抑制后，胰管细胞转变为类贝塔细胞的比例从原本不足 1% 提升至约 8.5%，能针对高血糖分泌胰岛素。

研究人员将经过基因改造的人类细胞移植至患有糖尿病的小鼠体内，发现小鼠体内开始循环人类胰岛素，其血糖值下降并维持在接近正常水平长达六周。相较于将肌肉细胞改造成胰岛素工厂或体外培养细胞移植等可能引发免疫反应的疗法，这项研究展示了直接利用胰脏现有细胞进行功能重塑的全新潜力。（关键数字： six weeks）

尽管前景看好，该技术仍面临重大挑战，包括 ALDH3B2 基因存在于人体多种细胞中，未来治疗必须精确锁定目标细胞以避免副作用。研究团队下一步将深入厘清该基因转化的分子机制，并探索透过基因疗法或开发特定小分子抑制剂来达成治疗效果，有望为全球数亿糖尿病患者带来长效治疗契机。

In diabetes patients, insulin-producing pancreatic beta cells are typically deficient or dysfunctional, prompting researchers at Harvard Medical School to use genetic screening to identify a key gene, ALDH3B2, that governs the conversion of pancreatic ductal cells into beta-like cells. Silencing ALDH3B2 increased the spontaneous transition rate of ductal cells into insulin-secreting beta-like cells from less than 1 percent to approximately 8.5 percent.

When these engineered human cells were transplanted into diabetic mice, human insulin circulated effectively, and the animals' blood glucose levels returned to near-normal ranges for six weeks. Unlike emerging therapies that modify muscle cells or rely on lab-grown cell transplants that carry risks of immune rejection, this approach highlights the viable potential of reprogramming existing cells directly within the pancreas by switching off identity-maintaining genes.

Despite its promise, significant hurdles remain, notably that ALDH3B2 is expressed throughout the body, making precise cell targeting essential to prevent off-target complications. The research team aims to clarify the precise mechanisms behind this cellular metamorphosis and pursue either gene therapy or small-molecule inhibitors to replicate the effect, offering hope for improved management for hundreds of millions of diabetes patients worldwide.